Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HALOZYME THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HALOZYME THERAPEUTICS's regulatory disclosures and financial reporting.
Halozyme Therapeutics, Inc. presents an annual overview of its business focused on drug-delivery technologies that convert intravenous therapies to subcutaneous injections. The company’s ENHANZE platform, based on its rHuPH20 enzyme, is widely licensed to major biopharma partners, generating upfront fees, milestones, bulk enzyme sales and royalties from ten commercial products.
Halozyme also develops Hypercon and Surf Bio hyperconcentration technologies and pressure-assisted auto-injectors, plus proprietary products Hylenex and XYOSTED. It highlights extensive global partnerships with Roche, Takeda, Janssen, argenx, BMS and others, alongside detailed risk factors spanning regulatory approval, supply chain, competition, financing, cybersecurity and market volatility.
Halozyme Therapeutics reported another year of strong top-line growth in 2025, with total revenue of $1.3966 billion, up 38% from 2024. Royalty revenue rose 52% to a record $867.8 million, driven mainly by ENHANZE-enabled products such as VYVGART Hytrulo, DARZALEX SC and Phesgo.
Despite this, full-year net income declined to $316.9 million from $444.1 million, as results absorbed $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition and higher operating costs. The company posted a fourth-quarter net loss of $141.6 million after these charges.
Halozyme expanded its drug-delivery portfolio by acquiring Elektrofi and Surf Bio and completed $1.5 billion of new convertible notes while increasing its revolving credit facility to $750 million. For 2026, it reiterates guidance for total revenue of $1.710–$1.810 billion, adjusted EBITDA of $1.125–$1.205 billion and non-GAAP diluted EPS of $7.75–$8.25, all implying robust double-digit growth over 2025.
Halozyme Therapeutics executive Cortney Caudill received new equity awards under the company’s compensation programs. On 02/09/2026, the SVP and Chief Operating Officer acquired an option to purchase 14,047 shares of common stock at $80.48 per share, vesting over four years starting 02/09/2027.
Caudill was also granted 13,047 restricted stock units that vest 25% on the first anniversary of the grant date and 25% on each anniversary thereafter. In addition, performance stock units tied to performance periods ending December 31, 2025 became eligible to vest, covering 2,403 and 14,751 shares, subject to continued service through the third anniversary of their original PSU grant dates.
Halozyme Therapeutics reported that SVP and Chief Legal Officer Mark Howard Snyder received several equity awards on February 9, 2026. He was granted an option to purchase 18,730 shares of common stock at an exercise price of $80.48, vesting one-fourth on the grant date and then monthly in equal installments.
He was also awarded 17,396 restricted stock units that vest in four equal annual installments starting one year after the grant, plus multiple performance stock unit awards. Performance stock units of 4,651, 7,808, and 29,502 shares became eligible to vest based on a performance period ending December 31, 2025 and remain subject to additional service-based vesting through the third anniversary of each original PSU grant date.
Halozyme Therapeutics executive Nicole LaBrosse, SVP and Chief Financial Officer, reported new equity awards tied to prior performance-based grants. On February 9, 2026, she acquired 5,167, 7,448, and 29,502 performance stock units at $0 per unit, each representing a contingent right to one share of common stock.
The units reflect the company’s determination of how many stock units became eligible to vest based on performance periods ending December 31, 2025 for PSU awards originally granted in 2023, 2024, and 2025. These awards remain subject to continued service through the third anniversary of each original grant date.
Halozyme Therapeutics President and CEO Helen Torley, who is also a director, reported receiving new equity awards on February 9, 2026. She was granted an option to purchase 53,847 shares of common stock at an exercise price of $80.48 per share.
Torley also acquired 50,013 restricted stock units, plus multiple performance stock unit (PSU) awards of 19,807, 24,985, and 92,714 units. These PSUs became eligible to vest based on a performance period ending December 31, 2025 and remain subject to ongoing service-based vesting, generally through the third anniversary of each PSU grant date.
Halozyme Therapeutics, Inc. President and CEO Helen Torley, who is also a director, reported a series of option exercises and related stock sales in early February 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025.
On February 3–5, 2026, she exercised company stock options at an exercise price of $12.07 per share and sold the resulting common shares in multiple transactions at weighted average prices generally in the mid-to-high $70s per share, as detailed in the price ranges disclosed for each trade.
Following these transactions, she directly held 708,719 shares of Halozyme common stock and 201,923 options to purchase common stock, with the options originally granted on February 22, 2017 and exercisable over a four-year vesting schedule.
A shareholder of Halozyme Therapeutics, Inc. filed a Form 144 notice to sell 150,000 shares of common stock through J.P. Morgan Securities on the NASDAQ, with an approximate sale date of 02/03/2026. The filing lists an aggregate market value of $11,167,500 for these shares and notes that 117,597,000 shares of common stock were outstanding. The shares to be sold were acquired on 02/03/2026 via a stock option exercise paid in cash. The same shareholder previously sold multiple blocks of Halozyme common stock in November and December 2025, including 20,000-share sales on several November dates and 16,569 shares on 12/01/2025 with reported gross proceeds for each transaction.
Halozyme Therapeutics provides preliminary, unaudited estimates for its 2025 results, including total revenue between $1,385 million and $1,400 million. The company estimates 2025 royalties of $865 million to $870 million, product sales of $372 million to $377 million, and collaboration revenue of $148 million to $153 million. These figures were shared in connection with 2026 financial guidance and remain subject to completion of year-end financial closing procedures.
Halozyme Therapeutics, Inc. reported that it has entered into a Transition and Release Agreement with its Senior Vice President and Chief Financial Officer, Nicole LaBrosse, in connection with her previously announced planned departure. She will continue as CFO until the earlier of the hiring of a new CFO, March 30, 2026, or an earlier date set by the company, after which she will leave to pursue another opportunity.
Under the agreement, Ms. LaBrosse is eligible to receive her 2025 annual bonus at 120% target-level individual performance, cash severance consistent with a termination not for cause, potential pro-rated 2026 bonus, accelerated vesting of certain equity awards if her separation occurs before February 28, 2026, and an extended one-year post-termination exercise window for vested stock options. If a Change in Control occurs within one year after her separation, all then-unvested options will vest, and the company will cover the cost of COBRA healthcare continuation for one year following her separation date.